---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-25-000069"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-17T00:04:19.053659+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lisata reports Q3 2025 net loss $4.2M; cash runway into Q1 2027 with new partnerships

## Summary
- Net loss $4.2M vs $4.9M in Q3 2024; operating expenses down 17% to $4.4M.
- Cash and equivalents $19.0M; management projects funding operations into Q1 2027.
- ASCEND mPDAC trial final data expected Q1 2026; BOLSTER topline data due Q4 2025.
- Licensed certepetide to Catalent for ADC platform; partnered with GATC Health for AI drug discovery.
- Preliminary CENDIFOX data showed 70% pathologic partial response and 60% 2-year OS in PDAC cohort.

## SEC filing metadata
- accession: 0000320017-25-000069
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001725000069/0000320017-25-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001725000069/clbs-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-25-000069
- JSON: https://secwatch.observer/filing/0000320017-25-000069.json
- Plain text: https://secwatch.observer/filing/0000320017-25-000069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.